 |
Joele Frank is handling Forma Therapeutics as the Watertown, MA-based biopharmaceutical company focused on sickle cell disease and other blood disorders is acquired by Novo Nordisk for $1.1B cash.
The Danish company has developed Etavopivat, which is currently being evaluated in global trials to treat sickle cell disease.
“Novo Nordisk has worked for more than 40 years to develop and deliver transformative medicines to patients around the world with rare and devastating diseases,” said Ludovic Helfgott, EVP and head of rare disease unit.
The addition of Forma’s ‘differentiated approach’ to address unmet needs for patients is a step forward in enhancing our sickle cell disease pipeline.” added Helftogg.
Joele Frank, Wilkinson Brimmer Katcher’s Jamie Moser and Greg Klassen represent Forma Therapeutics.
Interpublic posted a 5.1 percent drop in Q3 net revenues to $2.5B as CEO Philippe Krakowsky reports the final financial results of the publicly traded company.
Joele Frank handles Pine Gate Renewables as the Asheville, NC-based solar power development company declares Chapter 11 in the aftermath of Donald Trump’s cuts to wind & solar tax credits.
Stagwell CEO Mark Penn reports Q3 net revenues jumped 6 percent to $614.5M, a record performance for a non-political period. Operating income soared 45.7 percent to $60.9M.
Joele Frank works for Klöckner Pentaplast as the German maker of plastic films declares Chapter 11. A successful reorganization would slash its its corporate debt by $1.5B.
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
